Opus Genetics, Inc
Clinical trials sponsored by Opus Genetics, Inc, explained in plain language.
-
One-Shot gene injection tested for rare blinding eye conditions
Disease control Recruiting nowThis early-stage study is testing a one-time gene therapy injection called OPGx-BEST1 for two rare, inherited eye diseases (BVMD and ARB) that cause vision loss. The main goal is to check the safety and side effects of the treatment and find the best dose. Researchers will follow…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Doctors test One-Shot gene injection to fight rare blindness
Disease control Recruiting nowThis study is testing a new gene therapy called OPGx-001 for people with LCA5, a rare genetic condition that damages the retina and leads to vision loss. A small number of participants will receive an injection of the therapy into one eye to see if it is safe and if it might help…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC